Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study

OBJECTIVES: To determine whether the use of medications with possible and definite anticholinergic activity increases the risk of cognitive impairment and mortality in older people and whether risk is cumulative.

[1]  C. Napoli,et al.  Congestive Heart Failure and Cognitive Impairment in an Older Population , 1998 .

[2]  B. Pollock,et al.  Anticholinergic Activity of 107 Medications Commonly Used by Older Adults , 2008, Journal of the American Geriatrics Society.

[3]  M. Dewey,et al.  Self‐reported medication use for older people in England and Wales , 2001, Journal of clinical pharmacy and therapeutics.

[4]  G. Preston,et al.  Modelling dementia: Effects of scopolamine on memory and attention , 1988, Neuropsychologia.

[5]  S. Potkin,et al.  Alzheimer disease and other dementias. , 2003, Clinics in geriatric medicine.

[6]  T. Itil,et al.  ANTICHOLINERGIC DRUG‐INDUCED DELIRIUM: EXPERIMENTAL MODIFICATION, QUANTITATIVE EEG AND BEHAVIORAL CORRELATIONS , 1966, The Journal of nervous and mental disease.

[7]  N. Hooper,et al.  ADAMs family members as amyloid precursor protein α‐secretases , 2003 .

[8]  C. Napoli,et al.  Congestive heart failure and cognitive impairment in an older population. Osservatorio Geriatrico Campano Study Group. , 1998, Journal of the American Geriatrics Society.

[9]  K. Hall,et al.  Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. , 2002, Archives of internal medicine.

[10]  M. Boustani,et al.  Impact of anticholinergics on the aging brain: a review and practical application , 2008 .

[11]  F. Pasquier,et al.  Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. , 2009, Archives of internal medicine.

[12]  Y. Kloog,et al.  Mitogen‐Activated Protein Kinase‐Dependent and Protein Kinase C‐Dependent Pathways Link the m1 Muscarinic Receptor to β‐Amyloid Precursor Protein Secretion , 1998 .

[13]  M. Boustani,et al.  CHAPTER 16 – Alzheimer's Disease and Other Dementias , 2007 .

[14]  J. Touchon,et al.  Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study , 2006, BMJ : British Medical Journal.

[15]  J. Hanlon,et al.  Use of Inappropriate Prescription Drugs by Older People , 2002, Journal of the American Geriatrics Society.

[16]  C. Roe,et al.  Use of Anticholinergic Medications by Older Adults with Dementia , 2002, Journal of the American Geriatrics Society.

[17]  L. Tune,et al.  Acetylcholine and Delirium , 1999, Dementia and Geriatric Cognitive Disorders.

[18]  P. Sloane,et al.  Clinical Efficacy and Outcome in the Diagnosis and Treatment of Low Back Pain , 1992, Neurology.

[19]  Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). , 1998, Psychological medicine.

[20]  M. Mishkin,et al.  The effects of physostigmine and scopolamine on recognition memory in monkeys. , 1986, Behavioral and neural biology.

[21]  M. Boustani,et al.  The Association Between Cognition and Histamine‐2 Receptor Antagonists in African Americans , 2007, Journal of the American Geriatrics Society.

[22]  M. Boustani,et al.  Use of anticholinergics and the risk of cognitive impairment in an African American population , 2010, Neurology.

[23]  K. Davis,et al.  Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. , 1997, Brain research. Molecular brain research.

[24]  H. Fibiger,et al.  Behavioral pharmacology and biochemistry of central cholinergic neurotransmission. , 1991, Advances in experimental medicine and biology.

[25]  Ian G. McKeith,et al.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.

[26]  Teresa G Odle.  Alzheimer disease and other dementias. , 2003, Radiologic technology.

[27]  T. Chen,et al.  Targeting Suboptimal Prescribing in the Elderly: A Review of the Impact of Pharmacy Services , 2009, The Annals of pharmacotherapy.

[28]  Donna Fick,et al.  The cognitive impact of anticholinergics: A clinical review , 2009, Clinical interventions in aging.

[29]  N. Butters,et al.  Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. , 1986, Behavioral and neural biology.

[30]  M. Ryan,et al.  Long-term cognitive impact of anticholinergic medications in older adults. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[31]  R. Desimone,et al.  Scopolamine affects short-term memory but not inferior temporal neurons. , 1993, Neuroreport.

[32]  M. Weisbrod,et al.  Serum anticholinergic activity and cerebral cholinergic dysfunction: An EEG study in frail elderly with and without delirium , 2008, BMC Neuroscience.